Phase 3 N=626 The Efficacy of a Toothpaste to Reduce Sensitivity
Dentin Hypersensitivity
Primary: Hypersensitivity Tactile(Yeaple Probe) — 19.81; 13.94 units on a scale — p=0.05
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=448 Sugammadex Hypersensitivity Study (Study P06042)
Hypersensitivity
Primary: The Percentage of Participants With Adjudicated Hypersensitivity Signs/Symptoms, for Each Sugammadex Dose Group and Placebo. — 0.7; 4.7; 0 percentage of participants
Phase 2 N=75 Peanut Epicutaneous Phase II Immunotherapy Clinical Trial
Peanut Hypersensitivity · Food Hypersensitivity · Hypersensitivity
Primary: Percentage of Subjects With a Successful Treatment Response — 12.0; 45.8; 48.0 percentage of participants — p=0.005
Phase 2 N=201 Determination of the Sensitivity and Specificity of Prick Test Betula Verrucosa
Immune System Diseases
Primary: Sensitivity for 100 HEP/mL — 75; 0 positive reaction
Phase 2 N=253 Evaluation of the Allergenicity of AMPHADASE INJECTION (Hyaluronidase Injection USP)
Allergic Skin Reaction
Primary: Positive Allergic Reaction to Amphadase® in the Per-Protocol Population (PPP) — 0 participants
N/A N=19 Mast Cell Activation Test in Allergic Disease
Asthma · Mastocytosis · Mast Cell Activation Syndrome
Primary: Mast Cell Activation Test Results for Validation Group — 6; 2; 0; 4 Participants
Phase 2 N=686 COVID19 SARS Vaccinations: Systemic Allergic Reactions to SARS-CoV-2 Vaccinations
SARS-CoV Infection · COVID-19 · Allergic Reaction
Primary: Proportion of Participants Who Experienced a Systemic Allergic Reaction (CoFAR Grade 2+ Regardless of Tryptase or CoFAR Grade 1 With Elevated Tryptase) Within 90 Minutes…
Phase 1 N=259 Contact Sensitization Potential of 828 Ointment
Healthy Volunteers
Primary: Number of Participants That Exhibited a Score Less Than 1.5 on the Jordan-King Scale — 205 participants
Phase 4 N=119 TBE (Tick-borne Encephalitis) Vaccination in Allergic Patients
Vaccine Responsiveness in Allergy · Vaccine Responsiveness During Allergy De-sensitization Treatment
Primary: Humoral TBE Immunity — 317.90; 250.10; 282.20 titer
N/A N=20 Immunological Response After Shrimp Oral Immunotherapy Treatment
Allergy to Shrimp · Immunotherapy
Primary: Change in Eliciting Dose of Shrimp During Oral Food Challenge — 3233; 25 mg
N/A N=18 Immune Dysfunction in Allergic Asthma
Asthma
Primary: Anti-KLH Antibody. This is Measured by ELISA and Expressed as ELISA Units Which Are Derived by Dilution of Serum Samples Until the Result Falls on a Linear Portion of…
N/A N=81 SPT for Sensitization of Collagen Dressing
Allergy Skin · Allergic Skin Reaction
Primary: Wheal Measurement — 0; 7.91; 0.32 mm
N/A N=16 The Effects of Immunotherapy in the Nose
Rhinitis, Allergic, Seasonal
Primary: The Total Number of Differentially Expressed Transcripts. — 119; 49 transcripts
Phase 2 N=36 Peanut Reactivity Reduced by Oral Tolerance in an Anti-IgE Clinical Trial
Peanut Allergy · Food Allergy
Primary: Tolerance of 2000 mg 6 Weeks After Last Dose of Omalizumab/Placebo — 23; 1 Participants
Phase 1 N=48 Subcutaneous Immunotherapy in Patients Sensitized to Dermatophagoides Pteronyssinus (DPT)
Allergic Rhinoconjunctivitis
Primary: Number and Seriousness of Both Local and Systemic Adverse Reactions — 2; 1; 0; 1 adverse reactions number
Phase 1 N=382 A Study to Evaluate the Incidence of Hypersensitivity After Administration of Sugammadex in Healthy Participants (MK-8616-101)
Hypersensitivity · Anaphylaxis
Primary: Percentage of Participants With Adjudicated Symptoms of Hypersensitivity — 1.3; 6.6; 9.5 percentage of participants
Phase 3 N=108 Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES)
Hypereosinophilic Syndrome
Primary: Percentage of Participants Who Experienced an HES Flare or Who Withdrew From the Study During the 32-Week Study Treatment Period — 56; 28 Percentage of participants…
Phase 2 N=22 Clinical Evaluation of Lyral® Dose Response Study
Contact Dermatitis
Primary: Number of Participants With Positive Patch Test Responses — 14; 12; 11; 0 participants
Phase 2 N=60 Multi Immunotherapy to Test Tolerance and Xolair
Food Allergy
Primary: The Number of Participants Able to Tolerate an Oral Food Challenge to 2,000 mg at Least of 2 Allergens at Week 36 (i.e. the End of the Randomized Withdrawal/Tolerance…
N/A N=79 Clinical Efficacy of a Toothpaste on Hypersensitivity Reduction
Hypersensitivity
Primary: Tooth Hypersensitity to Touch Stimuli (Tactile) — 10.83; 10.63 Units on a scale — p=0.05
Phase 4 N=13 Therapeutic Utility of Xolair in Patients Undergoing Aspirin Desensitization
Aspirin Sensitivity
Primary: Number of Participants Without Respiratory Reaction During Aspirin Desensitization — 0; 5 Participants — p=0.036
Phase 2 N=12 Subcutaneous Immunotherapy for Mouse in Adults
Asthma · Perennial Allergic Rhinitis
Primary: Number of Reported Adverse Events (AEs) — 9; 1; 1; 2 Events
N/A N=101 A Comparison Study of Hypersensitivity Treatment
Dentin Hypersensitivity
Primary: Change in Pain From Baseline Immediately After Application of Test Product. — 8.9; 8.6 units on a scale
Phase 1 N=24 Phase I Clinical Human Tolerability Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10
Healthy
Primary: the Cases of Adverse Events With Participant Injection of ESAT6-CFP10 — 3; 1; 0; 0 cases
Phase 3 N=235 Clinical Evaluation of T.R.U.E. TEST® : Safety and Efficacy
Contact Dermatitis
Primary: Diagnostic Performance: Concordance Between Investigational Allergen and Reference Allergen at Day 21 — 78.9 percentage of concordant responses
Phase 3 N=450 Evaluation of Skin Testing Reagents for Penicillin Allergy
History of IgE Dependent Reaction to a Penicillin Product
Primary: Negative Predictive Value — 98.0 percentage of participants
Phase 4 N=275 Study to Evaluate the Effect of Omalizumab on Improving the Tolerability of Specific Immunotherapy in Patients With Persistent Allergic Asthma
Allergic Asthma
Primary: Number of Participants With Systemic Allergic Reactions (SAR) to Specific Immunotherapy (SIT) — 32; 17; 49 participants
Phase 3 N=112 A Study Investigating the Immunologic Effects and Safety of 60-day Treatment of the ALK HDM Tablets in Adult Subjects With HDM-Induced Allergic Rhinitis and/or Atopic Asthma
Allergy · Asthma · Rhinitis
Primary: D. Farinae Specific IgG4 Change From Baseline to End of Treatment — 0.473; -0.01 mg antibody/ml
Phase 2 N=10 Preventing Anaphylaxis With Acalabrutinib
Food Allergy · Food Allergy Peanut
Primary: Highest Dose of Peanut That is Tolerated During Oral Food Challenge — 29; 4,044 mg — p=0.002
N/A N=24 Randomized Evaluation of Ten Allergy Skin Prick Test Devices
Allergic Rhinitis · Asthma · Food Allergy
Primary: Wheal Response — 6.8 mm